While agency advisers raised concerns over molnupiravir’s modest benefits and potential risks, a majority felt the antiviral drug is a needed option for COVID-19 patients at high risk of severe disease.
While agency advisers raised concerns over molnupiravir’s modest benefits and potential risks, a majority felt the antiviral drug is a needed option for COVID-19 patients at high risk of severe disease.
Copyright © 2024 | WordPress Theme by MH Themes